英国首发精神分裂症十种常用抗精神病药的成本效果:基于新构建离散事件模拟模型的经济学评价
研究构建了英国首发精神分裂症的离散事件模拟模型,纳入复发、缓解、停药、心血管病和死亡等事件,从国家卫生服务视角估算十年成本和QALYs,对十种一线抗精神病药排序。氨磺必利QALYs最高且最具成本效果,其次为奥氮平和利培酮长效注射剂;卡利拉嗪、鲁拉西酮和喹硫平成本效果最差。
要点
- 氨磺必利QALYs最高(6.121),利培酮长效注射剂(6.084)和阿立哌唑长效注射剂(6.070)次之。
- 最具成本效果为氨磺必利、奥氮平和利培酮长效注射剂,排名≤3的概率合计80%。
- 最不具成本效果为卡利拉嗪、鲁拉西酮和喹硫平,排名≥8的概率合计81%。
核心结论
- 作者认为基于QALYs和成本效果,氨磺必利(或口服治疗不合适时用利培酮长效注射剂)是最佳整体一线选择。
- 作者认为该排序可用于指导抗精神病药之间的决策。
- 作者指出模型为开源,可应用于其他场景。
研究设计与样本
- 研究构建了新离散事件模拟(DES)模型,基于既往模型结构,纳入英国人口学、临床和成本数据,抗精神病药效应来自近期网络Meta分析。
- 模拟首发精神分裂症患者的治疗路径,包括复发、缓解、治疗停药、心血管疾病和死亡等事件。
- 从国家卫生服务视角估算十年成本(2020年英镑)和质量调整生命年(QALYs)。
- 利用模型对十种一线抗精神病药按QALYs和成本效果进行排序。
主要发现
- 氨磺必利QALYs最高,其次为利培酮长效注射剂(LAI)和阿立哌唑-LAI,分别为6.121、6.084、6.070,其他药物为5.947-6.058。
- 最具成本效果的抗精神病药为氨磺必利、奥氮平和利培酮-LAI,排名为1、≤2、≤3的总概率分别为95%、89%、80%。
- 最不具成本效果的为卡利拉嗪、鲁拉西酮和喹硫平,排名为10、≥9、≥8的总概率分别为96%、92%、81%。
- 结果在敏感性分析中稳健,主要受复发相关参数影响。
临床怎么用
- 作者认为基于QALYs和成本效果,氨磺必利(或口服治疗不合适时用利培酮长效注射剂)是最佳整体一线选择。
- 作者认为该排序可用于指导抗精神病药之间的决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous economic evidence about interventions for schizophrenia is outdated, non-transparent and/or limited to a specific clinical context. AIMS: We developed a de novo discrete event simulation (DES) model for estimating the cost-effectiveness of interventions in schizophrenia in the UK. METHOD: The DES model was developed based on the structure of previous models, populated with demographic, clinical and cost data from the UK, and antipsychotics' effects from recent network meta-analyses. We simulated treatment pathways for patients with first-episode schizophrenia including events such as relapse, remission, treatment discontinuation, cardiovascular disease and death and estimated costs (2020£) taking the National Health Service perspective and quality-adjusted life years (QALYs) over ten years. Using the model, we ranked ten first-line antipsychotics based on their QALYs and cost-effectiveness. RESULTS: Amisulpride was associated with the highest QALYs, followed by risperidone long-acting injection (LAI), aripiprazole-LAI (6.121, 6.084, 6.070, respectively) and others (5.947-6.058). The most cost-effective antipsychotics were amisulpride, olanzapine and risperidone-LAI, with total probability of rankings of 1, ≤2, ≤3, that is, 95%, 89%, 80%, respectively; meanwhile, the least cost-effective were cariprazine, lurasidone and quetiapine, with total probability of rankings of 10, ≥9, ≥8, that is, 96%, 92%, 81%, respectively. Results were robust across sensitivity analyses and influenced primarily by relapse relevant parameters. CONCLUSIONS: Our findings suggest amisulpride (or risperidone-LAI where oral treatment is inappropriate) as the best overall first-line option based on QALYs and cost-effectiveness. Our ranking may be used to guide decision-making between antipsychotics. Our model is open source and could be applied to the other settings.
引用
- Zhou J, Millier A, Aballea S, et al. Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a de novo discrete event simulation model. Br J Psychiatry. 2025. PMID: 39721946. doi:10.1192/bjp.2024.251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。